CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-703-5069460
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date12/19/2019 (Estimated)
OptionableOptionable
CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) issued its earnings results on Wednesday, August, 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.27. The firm earned $0.11 million during the quarter, compared to analyst estimates of $0.10 million. View CEL-SCI's Earnings History.
When is CEL-SCI's next earnings date?
Has CEL-SCI been receiving favorable news coverage?
Media headlines about CVM stock have been trending very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CEL-SCI earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for CEL-SCI.
Are investors shorting CEL-SCI?
CEL-SCI saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 6,680,000 shares, an increase of 8.4% from the September 15th total of 6,160,000 shares. Based on an average daily trading volume, of 719,800 shares, the days-to-cover ratio is currently 9.3 days. Approximately 20.0% of the shares of the company are sold short. View CEL-SCI's Current Options Chain.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Immutep (IMM), Mesoblast (MSB), Kodiak Sciences (KOD), Paradigm Biopharmaceuticals (PAR), Starpharma (SPL), BELLUS Health (BLU), TELIX Pharmaceutical (TLX), Biotest (BIO), Oxford BioMedica (OXB), Theratechnologies (TH), Bellus Health (BLU), Neptune Wellness Solutions (NEPT), Resverlogix (RVX), ProMetic Life Sciences (PLI) and Rafael (RFL).
What other stocks do shareholders of CEL-SCI own?
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the folowing people:
- Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
- Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
- Dr. Eyal Talor, Chief Scientific Officer (Age 63)
- Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
- Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include D.A. Davidson & CO. (1.52%), Commonwealth Equity Services LLC (0.48%), Rhumbline Advisers (0.07%) and Endurance Wealth Management Inc. (0.04%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Eyal Talor, Geert R Kersten, John Cipriano and Peter R Young. View Institutional Ownership Trends for CEL-SCI.
Which institutional investors are buying CEL-SCI stock?
CVM stock was purchased by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, D.A. Davidson & CO., Endurance Wealth Management Inc. and Rhumbline Advisers. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten and Peter R Young. View Insider Buying and Selling for CEL-SCI.
How do I buy shares of CEL-SCI?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CEL-SCI's stock price today?
One share of CVM stock can currently be purchased for approximately $7.12.
How big of a company is CEL-SCI?
What is CEL-SCI's official website?
How can I contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
